GENMAB A/S(GMAB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
GMAB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for GENMAB A/S (GMAB), a Healthcare sector company. GMAB is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (FY 2025), GENMAB A/S reports quarterly revenue of $3.7B, net income of $963.0M. Top institutional holders of GMAB by reported 13-F value include Orbis Allan Gray Ltd, ALLIANCEBERNSTEIN L.P., Paradigm Biocapital Advisors, based on the most recent SEC filings. GMAB trades on the Nasdaq exchange and files with the SEC under CIK 1434265. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GMAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GENMAB A/S directly from SEC EDGAR.
Revenue
FY 2025
$3.7B
Net Income
FY 2025
$963.0M
Get alerted when GMAB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for GENMAB A/S including:
Top Institutional Holders of GMAB
Orbis Allan Gray Ltd
$346.8M12,925,578 shALLIANCEBERNSTEIN L.P.
$294.4M9,557,149 shParadigm Biocapital Advisors LP
$213.8M7,967,836 shARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$133.5M4,975,324 shBlackRock, Inc.
$121.7M4,536,565 shRENAISSANCE TECHNOLOGIES LLC
$118.4M4,414,550 shDeep Track Capital, LP
$98.3M3,663,250 shHARDING LOEVNER LP
$86.7M3,231,601 shDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$66.1M2,462,000 shFIRST TRUST ADVISORS LP
$66.0M2,461,342 sh
| Fund | Value | Shares |
|---|---|---|
| Orbis Allan Gray Ltd | $346.8M | 12,925,578 |
| ALLIANCEBERNSTEIN L.P. | $294.4M | 9,557,149 |
| Paradigm Biocapital Advisors LP | $213.8M | 7,967,836 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $133.5M | 4,975,324 |
| BlackRock, Inc. | $121.7M | 4,536,565 |
| RENAISSANCE TECHNOLOGIES LLC | $118.4M | 4,414,550 |
| Deep Track Capital, LP | $98.3M | 3,663,250 |
| HARDING LOEVNER LP | $86.7M | 3,231,601 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $66.1M | 2,462,000 |
| FIRST TRUST ADVISORS LP | $66.0M | 2,461,342 |
More Healthcare Companies
View all Healthcare →Put GMAB on your watchlist
Track score changes the day GENMAB A/S files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GMAB a good stock to buy?
13F Pro's AI-powered analysis of GENMAB A/S (GMAB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GMAB are available on the GMAB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own GMAB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GMAB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GENMAB A/S's investment landscape.